| Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer's disease P Spilman, N Podlutskaya, MJ Hart, J Debnath, O Gorostiza, D Bredesen, ... PloS one 5 (4), e9979, 2010 | 1138 | 2010 |
| Mechanisms of vascular aging Z Ungvari, S Tarantini, AJ Donato, V Galvan, A Csiszar Circulation research 123 (7), 849-867, 2018 | 675 | 2018 |
| Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw, Ind) mice K Jin, V Galvan, L Xie, XO Mao, OF Gorostiza, DE Bredesen, ... Proceedings of the National Academy of Sciences 101 (36), 13363-13367, 2004 | 602 | 2004 |
| Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664 V Galvan, OF Gorostiza, S Banwait, M Ataie, AV Logvinova, S Sitaraman, ... Proceedings of the National Academy of Sciences 103 (18), 7130-7135, 2006 | 295 | 2006 |
| Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner V Galvan, B Roizman Proceedings of the National Academy of Sciences 95 (7), 3931-3936, 1998 | 295 | 1998 |
| Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease J Beauquis, P Pavía, C Pomilio, A Vinuesa, N Podlutskaya, V Galvan, ... Experimental Neurology 239, 28-37, 2013 | 240 | 2013 |
| Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice J Halloran, SA Hussong, R Burbank, N Podlutskaya, KE Fischer, ... Neuroscience 223, 102-113, 2012 | 223 | 2012 |
| Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer’s disease AL Lin, W Zheng, JJ Halloran, RR Burbank, SA Hussong, MJ Hart, ... Journal of Cerebral Blood Flow & Metabolism 33 (9), 1412-1421, 2013 | 222 | 2013 |
| Transplantation of human neural precursor cells in Matrigel scaffolding improves outcome from focal cerebral ischemia after delayed postischemic treatment in rats K Jin, XO Mao, L Xie, V Galvan, B Lai, Y Wang, O Gorostiza, X Wang, ... Journal of Cerebral Blood Flow & Metabolism 30 (3), 534-544, 2010 | 213 | 2010 |
| In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid β-peptide of APP DA Butterfield, V Galvan, MB Lange, H Tang, RA Sowell, P Spilman, ... Free Radical Biology and Medicine 48 (1), 136-144, 2010 | 211 | 2010 |
| Glycoprotein D or J Delivered in transBlocks Apoptosis in SK-N-SH Cells Induced by a Herpes Simplex Virus 1 Mutant Lacking Intact Genes Expressing Both … G Zhou, V Galvan, G Campadelli-Fiume, B Roizman Journal of virology 74 (24), 11782-11791, 2000 | 205 | 2000 |
| Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP MJ Saganich, BE Schroeder, V Galvan, DE Bredesen, EH Koo, ... Journal of Neuroscience 26 (52), 13428-13436, 2006 | 153 | 2006 |
| Aβ induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597–624) GM Shaked, MP Kummer, DC Lu, V Galvan, DE Bredesen, EH Koo The FASEB journal: official publication of the Federation of American …, 2006 | 153 | 2006 |
| Rapamycin and Alzheimer’s disease: time for a clinical trial? M Kaeberlein, V Galvan Science translational medicine 11 (476), eaar4289, 2019 | 151 | 2019 |
| Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease AL Lin, JB Jahrling, W Zhang, N DeRosa, V Bakshi, P Romero, V Galvan, ... Journal of Cerebral Blood Flow & Metabolism 37 (1), 217-226, 2017 | 147 | 2017 |
| Neurogenesis in the aging brain V Galvan, K Jin Clinical interventions in aging 2 (4), 605-610, 2007 | 147 | 2007 |
| Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain DL Vogt, D Thomas, V Galvan, DE Bredesen, BT Lamb, SW Pimplikar Neurobiology of aging 32 (9), 1725-1729, 2011 | 140 | 2011 |
| Polyphosphate: a conserved modifier of amyloidogenic processes CM Cremers, D Knoefler, S Gates, N Martin, JU Dahl, J Lempart, L Xie, ... Molecular cell 63 (5), 768-780, 2016 | 138 | 2016 |
| Detailed recollection of remote autobiographical memory after damage to the medial temporal lobe CB Kirwan, PJ Bayley, VV Galván, LR Squire Proceedings of the National Academy of Sciences 105 (7), 2676-2680, 2008 | 136 | 2008 |
| How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story A Richardson, V Galvan, AL Lin, S Oddo Experimental gerontology 68, 51-58, 2015 | 131 | 2015 |
